Category Archives: Immunology

UGA and EpiVax announce collaboration to develop COVID-19 vaccine – Red and Black

The University of Georgias Center for Vaccines and Immunology is collaborating with the Rhode Island-based pharmaceutical company EpiVax to develop a COVID-19 vaccine.

EpiVax has previously worked on vaccine reengineering with the Avian influenza, and a press release said EpiVax will implement their rapid analysis and vaccine design to the COVID-19 vaccine.

The press release said CVI Director Ted Rosss lab has already obtained the COVID-19 virus, and they will work in a high-security containment facility to begin testing.

As of press time, Georgia has two patients with COVID-19, one of whom recently returned from Italy. This morning, a press release from the Office of Governor Brian Kemp stated that the Georgia Department of Public Health is waiting for a confirmation from the Centers for Disease Control and Prevention of a positive test for COVID-19 in Floyd County, Georgia.

The initial test was completed by the Georgia Public Health Laboratory on March 5, and CDC protocols require CDC verification before confirming the presumptive positive COVID-19 cases.

President Donald Trump is touring the Centers for Disease Control and Prevention in Atlanta on March 6. The trip was briefly canceled after it appeared a CDC employee developed symptoms of the virus; however, test results later cleared the employee.

The rest is here:
UGA and EpiVax announce collaboration to develop COVID-19 vaccine - Red and Black

EpiVax partners with UGA researcher on Covid-19 vaccine – Pharmaceutical Technology

]]> EpiVax works towards a new vaccine against the novel coronavirus. Credit: CDC on Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreakon ourtimeline.

EpiVax has partnered with University of Georgia (UGA) researcher Ted Ross for the development of a vaccine against Covid-19 caused by the coronavirus.

Ted Ross is a vaccine expert and director of UGAs Center for Vaccines and Immunology (CVI).

EpiVax developed in silico / computational tools to detect the viral sequence regions that need to be included in vaccines while avoiding sequences linked to less effectiveness or safety.

Previously, the company used its vaccine reengineering approach to Avian influenza (H7N9) under a programme with UGA and UMASS Medical School. The programme receives its funds from the US National Institutes of Health (NIH).

According to EpiVax, rapid analysis and vaccine design were effective for H7N9, expected to aid the Covid-19 vaccine candidate.

EpiVax and the Ross lab have sought more funds from the NIH to support the rapid development of their Covid-19 candidate.

Ross lab had already obtained the novel coronavirus for testing. The new vaccine candidate will be produced and tested at the lab.

In a separate development, Generex Biotechnology entered into a contract with EpiVax to leverage computational tools for identifying epitopes that can produce peptide vaccines against Covid-19.

Generex will also use its NuGenerexImmuno-Oncology Ii-Key technology.

EpiVax has detected multiple hotspots in the amino acid sequences of coronavirus proteins.

Generex will now use epitopes predicted by EpiVax to generate a series of synthetic amino acid peptides that can imitate the virus epitopes. These peptides will be sent to China for testing with blood samples of coronavirus patients who have recovered.

The blood samples are expected to contain immune cells and antibodies that will recognise the peptides, proteins and nucleic acids of the virus.

With blood sample testing, the company aims to validate if the predicted sequences will be suitable vaccine peptides.

Last month, Generex signed a contract with four companies in China for the development of an Ii-Key Peptide-based Covid-19 vaccine.

View post:
EpiVax partners with UGA researcher on Covid-19 vaccine - Pharmaceutical Technology

Scientists say they’ve identified 2 strains of COVID-19 – Abccolumbia.com

One strain was common in Wuhan, China, then dropped off significantly.

By Erin SchumakerABC News Scientists from China said theyve identified two strains of COVID-19 linked to the recent outbreak.

Coronaviruses are a large family of RNA viruses, and when RNA viruses replicate quickly, they often mutate.

Researchers analyzed 103 sequenced genomes using strains from China, and found that 70% of strains were one type, which they called L. The L strain was more aggressive than the remaining 30% of strains, which were dubbed S.

The first strain was more common at the beginning of the outbreak, in Wuhan, China, but its frequency decreased after early January. That drop-off could be a result of the strict measures China put in place to try and stem the spread of the virus.

The new paper, published Tuesday in the National Science Review from the Chinese Academy of Sciences, is preliminary, the papers authors cautioned.

The scientists only analyzed strains from China, so more information is needed about strains from other countries to determine whether the same viruses have spread worldwide.

Dr. Stanley Perlman, a professor of microbiology and immunology at the University of Iowa who has researched SARS and MERS, said that the new paper didnt prove that one strain was more aggressive or faster spreading than the other.

For now, it looks like there are two strains, but we do not know exactly what this means, said Perlman, who is not connected to the new paper.

Go here to read the rest:
Scientists say they've identified 2 strains of COVID-19 - Abccolumbia.com

Physicians’ Education Resource to Present Live Symposium on Asthma at the 2020 American Academy of Allergy, Asthma & Immunology Annual Meeting -…

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

Go here to read the rest:
Physicians' Education Resource to Present Live Symposium on Asthma at the 2020 American Academy of Allergy, Asthma & Immunology Annual Meeting -...

Groundbreaking Study Finds Peanut Allergy Likely Starts In The Gut – Allergic Living

Photo: Getty

Scientists have long knownthat when it comes to allergic reactions, the IgE antibody is the main culprit.But a groundbreaking new study has found the gut plays a powerful role in theprocess. Researchers at Stanford University say their findings could not onlyhelp determine the root cause of allergies, but also lead to life-changingtreatments.

The California research teamused an endoscope to take tissue samples from the esophagus, stomach and smallintestine of 19 peanut-allergic people taking part in an oral immunotherapytrial. Then they closely examined those cells and compared them with ones foundin the blood.

According to study lead author Ramona Hoh, PhD, they found that peoples rapid response to allergens is due in part to a memory response thats contained in specific kinds of B cells in the gut. When those B cells encounter an antigen like peanut in a person with peanut allergy, they can switch into plasma cells and start pumping out reaction-inducing IgE antibodies.

So this may be how these IgE antibodies get produced so quickly, because theyre actually residing in the stomach and duodenum tissue, Hoh, a senior scientist in the department of pathology at Stanford University, told Allergic Living. She notes that the number of these IgE-producing cells was hundreds of times higher in the gut than whats typically found in the bloodstream.

Using genetic analysis, the researchers were also able to confirm that the cells were being made in the stomach and the duodenum of the small intestine. This showed they were not being generated elsewhere in the body, and then traveling to the gut.

Whats more, many of thepatients shared similar peanut-reactive IgE DNA sequences, which means theirimmune systems see peanut proteins in a similar way.

We think thats extremely interesting because with antibodies youre dealing with this hugely complex, diverse universe, study co-author Dr. Scott Boyd told Allergic Living. But if you look at enough people, you start to recognize the common patterns that are associated with the disease.

We think that may allow usto say whos a better candidate for a certain kind of treatment, for example,or may allow us to better distinguish who is just sensitized to the allergen,but may not react strongly if they eat it, said Boyd, the principalinvestigator at Stanford Medicines Scott Boyd Labratory for Human Immunology.

Titled Origins andclonal convergence of gastrointestinal IgE+ B cells in human peanut allergythe studywas published in the journal ScienceImmunology. While it focused on peanut allergy specifically, Hoh and Boydbelieve the process could be similar for other allergens.

We set out to study peanutallergy because of its high incidence in the population, says Boyd. But inprincipal, we could have done the same study for tree nut allergy or shellfishallergy or others, and we suspect that we would have had similar findings, thatthere would be a lot of these IgE-expressing B cells in the gut.

Hoh adds that the gut of a non-allergicperson looks decidedly different. That difference was most clear in thestomach and the stomach isnt really a tissue thats known to have a lot ofplasma cells or B cells of any type, she says. So it was a pretty dramaticfinding.

IgE is the main catalyst behind allergic reactions. When people have allergies to peanuts or other substances, they develop IgE antibodies that recognize the proteins and other components of those specific allergens. The IgE then binds to the surface of mast cells. With exposure to the allergen, those cells then release inflammatory substances such as histamine. These set off reactions that can range from swollen eyes to hives or digestive symptoms and, in more serious cases, anaphylaxis.

In people without allergies, B cells are most often involved with helping to protect against infectious disease. For example, if you get a vaccination for measles or mumps, the B cells get stimulated by the vaccine and pump disease-fighting antibodies into your blood cells.

By analyzing the B cells that produce the allergen-specific IgE, the Stanford team hoped to help find the root cause of allergies. Until now, researchers have been almost entirely restricted to looking at the cells they can detect in the blood of patients, because getting samples of tissues in the gut is extremely challenging. Their efforts paid off.

We know the human body iscomplicated, and a much bigger space than the blood alone. And there arecertain tissues, like those in the digestive system where, if someone has foodallergy, the reaction starts, says Boyd. And we had reason to suspect theremay be a whole separate aspect of the immune system thats localized to thetissues of the gut and the digestive system, and that those would be worthstudying.

Besides furthering the understanding of how allergic reactions work, Boyd and Hoh say the research could lead to better diagnosis, treatment and prevention. They raise the possibilty for treatments that could prevent the IgE antibodies from triggering reactions.

Boyd points to a recentstudy involving patients with cat allergies, in which participants weregiven a biologic drug that blocked the IgE response and significantly reduced theseverity of their allergic reactions. Theres no reason one couldnt try to dothe same thing for peanut allergy, says Boyd. It might be a bit morecomplicated because there are more allergen molecules involved, but it wouldseem like a viable thing to try.

In recent years, scientistshave developed a far greater understanding of the role the humanmicrobiome plays in the allergic process, and Boyd says theyre starting toreally hone in on potentially life-changing answers, which could lead totargeted treatments.

My guess is there are goingbe more new treatments approved for allergy, and things that might be moresuitable for one patient compared to another in the years ahead, says Boyd.So I think theres room for guarded optimism in patients who suffer from thesedisorders.

See the full study here.

Continue reading here:
Groundbreaking Study Finds Peanut Allergy Likely Starts In The Gut - Allergic Living

Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19 – BioSpace

NEW YORK & CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China--(BUSINESS WIRE)-- Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200306005051/en/

The collaboration will also utilize the H2L2 Harbour Mice platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 COVID-19 (commonly known as COVID-19). These fully human monoclonal antibodies could be used therapeutically for people who have been exposed to the virus, or prophylactically for individuals with a high risk of exposure, such as healthcare workers. The antibodies have the potential to prevent spread of the virus by blocking infection of cells.

We are pleased to be able to collaborate with HBM at this time and leverage our experience in therapeutic antibody generation as well as the viral expertise of the Microbiology Department with the unique human antibody producing mice from Harbour, said Professor Thomas Moran, PhD, Director, Center for Therapeutic Antibody Development (CTAD) at Icahn School of Medicine at Mount Sinai.

This is a unique collaboration that will give HBM access to Mount Sinais innovative research driven from its clinical practices. The agreement demonstrates HBMs commitment to develop novel medicines and foster fast-track innovative research. We will push the boundaries of science and the development of new medicines that will ultimately translate into better treatments for patients, said Jingsong Wang, MD, PhD, Founder, Chairman & Chief Executive Officer of HBM.

The relationship with HBM is yet another opportunity for Mount Sinai to develop new treatments for significant diseases and conditions, said Erik Lium, PhD, President, Mount Sinai Innovation Partners. This work will bring Mount Sinais innovation ecosystem one step closer to the drug development process.

About Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

About Mount Sinai Innovation Partners

Mount Sinai Innovation Partners (MSIP) is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit http://www.ip.mountsinai.org.

About Harbour BioMed

Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases. The company is building its proprietary pipeline through internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

The company's internal discovery programs are centered around its two patented transgenic mouse platforms (Harbour Mice) for generating both fully human monoclonal antibodies and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies. Harbour BioMed also licenses the platforms to companies and academic institutions. The company has operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou & Shanghai, China.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200306005051/en/

See more here:
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19 - BioSpace

Busting the Myths of Coronavirus and Goods Imported from China – Grainmart News

With increasing deaths and the number of infected individuals, coronavirus has left the worlds economy dwindling. This calls for busting myths of coronavirus, food and imported goods from China.

Several experts stated that there is no chance that virus could be transmitted from touching any surface of packaged shipped product. Further, they declared that no type of active delectable virus could travel via surface. David Evans, a professor in the Department of Medical Microbiology and Immunology at the University of Alberta states that coronavirus has a lipid bilayer a fatty membrane. Also, it is fragile and damaged easily. If it disperses on a surface, it dries and gets inactive stuck on that surface. However, the myths of coronavirus spread faster than the actuality.

India imported raw and powdered garlic from China in huge quantities. However, the coronavirus fears have stopped the supply of Chinese garlic, which were in great demand until now. Despite its toxicity levels due to bleaching, people prefer to use it over Indian variety because of its easiness to peel. However, the news of coronavirus outbreak has vanished Chinese garlic from the markets.

Ongoing myth about spreading of coronavirus by consuming chinese garlic is false. The conflicting misinformation out there resulted in digital platforms tightening the noose. Further, platforms like Twitter, Google and Instagram have started redirecting users to their home countries health authorities.

The widespread circulation of myths regarding the Coronavirus (Covid-19) has resulted in decreasing sales of chicken and meat. Citing this, the Poultry Farm Association organized chicken mela in Uttar Pradesh where it provided cooked chicken meals at a very low cost. Also, the top chicken companies have declared on their social media handles that properly cooked meat is safe for consumption.

The increasing myths of coronavirus are making people careless towards the threat. Also, the rumors about homeopathic medicines preventing the virus have spread. So, to clear out the doubts, the Ministry of AYUSH has issued an advisory that there is no medicine to prevent the coronavirus. Hence, people must take precautions rather than popping pills to boost their immunity. People have fallen prey to the misinformation on social media platforms. Thus, people need to identify the source of information before taking action.

In conclusion, Washing hands, wearing masks in public, staying away from public events and keeping distance from sick people is the right approach.

Go here to read the rest:
Busting the Myths of Coronavirus and Goods Imported from China - Grainmart News

Children with a rare food allergy have higher chance of being diagnosed with other allergies – The Medical News

Researchers at Children's Hospital of Philadelphia (CHOP) have found that children with a rare food allergy known as food protein-induced enterocolitis syndrome, or FPIES, have a significantly higher chance of being diagnosed with other allergic conditions, including eczema, traditional food allergy and asthma. But the researchers also found that FPIES did not directly cause those other allergies.

The study was published in the March issue of The Journal of Allergy and Clinical Immunology: In Practice.

"This work refines our view of the natural history of FPIES and expands our understanding of the relationship between this condition and other allergic diseases," said first author Melanie Ruffner, M.D., Ph.D., attending physician in the Division of Allergy and Immunology and the Center for Pediatric Eosinophilic Disorders at CHOP. "It's important for clinicians to keep in mind that patients with FPIES have a higher frequency of allergic manifestations and therefore provide appropriate screening and care as needed."

FPIES causes repetitive vomiting, diarrhea, and lethargy several hours after eating a trigger food, frequently cow's milk, soy, and grains. The condition typically develops during infancy, though it can occasionally occur in older children and adults.

Although previous research has collectively shown patients with FPIES have increased rates of eczema, other food allergies and asthma - so-called atopic allergies - researchers have not investigated the association between FPIES and other allergies to look for a potential causal link.

To do so, Ruffner and her collaborators looked at a cohort of more than 150,000 pediatric patients, of which 214 had FPIES. The investigators compared the rate of atopic allergies in FPIES patients to those without FPIES. They also followed the patients over time to see if there were differences in the timing of when FPIES patients developed atopic allergies compared to other patients.

The authors found that those with FPIES had substantially higher allergy rates than patients without the condition. FPIES patients were diagnosed with traditional food allergy at about six times the rate of those without FPIES and with atopic dermatitis at about twice the rate. There was a slightly smaller increase in the rate of asthma diagnoses, but those with FPIES were still diagnosed at a higher rate than those without the disease.

However, when the research team looked at the timing of the development of allergies, and whether a diagnosis of FPIES would lead to atopic allergies later in life, they did not find a causal link between the two. Thus, unlike the so-called atopic march - the progression of atopic disorders from eczema in infants to hay fever, food allergy and asthma in older children - FPIES does not cause other allergic disorders but instead is associated with them.

Although there is an increased rate of atopic allergies in patients with FPIES, our analyses demonstrate that a prior diagnosis of FPIES does not increase the rate of atopic allergies later in life. This pattern of association supports a yet-unknown cause, such as a shared predisposition to both types of allergy."

David Hill, M.D., Ph.D., corresponding author, attending physician in CHOP's Division of Allergy and Immunology

Source:

Journal reference:

Ruffner, M.A., et al. (2020) Elevated Atopic Comorbidity in Patients with Food ProteinInduced Enterocolitis. Journal of Allergy and Clinical Immunology: In Practice. doi.org/10.1016/j.jaip.2019.10.047.

See original here:
Children with a rare food allergy have higher chance of being diagnosed with other allergies - The Medical News

Marijuana Allergies on the Rise – Medscape

"Cannabis sativa is a weed and it causes reactions just like any other pollen allergy," said William Silvers, MD, from the University of Colorado School of Medicine in Aurora.

Silvers' clinic began to see people with allergic reactions to the plant after the increase in direct exposure that accompanied the legalization of recreational marijuana in Colorado. For people with allergic tendencies, first- and second-hand exposure to C.sativa will increase "classic responses," such as allergic rhinitis, sneezing, wheezing, itching, and asthma, he told Medscape Medical News.

Smoking the weed, direct exposure to the plant, contact with others who have touched plants, and breathing air in a grow operation "can all cause reactions," he said. "And the more exposure they had, the greater the reaction, especially those who have allergic tendency," he said.

The type of exposure to C.sativa is also a factor. Smoking the plant can induce typical allergic responses, the ingestion of hemp seed has been known to induce anaphylaxis, and "working with the plant can lead to dermatitis or contact urticaria," he explained.

The health risks and benefits associated with C.sativa will be discussed at the upcoming American Academy of Allergy, Asthma and Immunology (AAAAI) 2020 Meeting in Philadelphia. The new AAAAI cannabis working group will also meet during the event to discuss the next steps for patient care.

Edibles made with C.sativa have led to overdoses because dosing is difficult to determine. "It takes an hour or so to have an effect, so you don't have as much control as inhaling it," Silvers explained.

A 2018 case report describes a 24-year-old daily marijuana smoker who experienced anaphylaxis after ingesting hemp seed. He had a history of allergies to stoned fruits, nuts, crustaceans, and aeroallergens. It was his first known exposure to hemp seed.

The patient developed urticaria on his arms after contact with C.sativa leaves and flowers, but had no reaction when smoking marijuana. This case indicates how important mode of exposure is.

"There are only a few cases of anaphylaxis known from ingestion of hemp seed," Silvers said, "but the 'stoned fruit, stoned patients' cross-reactivity looks to be a real thing."

People allergic to ragweed and sage are more likely than others to have a reaction to cantaloupe and other fruits in the melon family, he explained. There is a common antigen in the C.sativa pollen and in certain foods with cross-reacting proteins, such as tomato, peach, and hazelnut. "We see a pollen and food cross-reactivity via nonspecific lipid transfer proteins."

A 2017 review of C.sativa allergy points out that few reports of IgE-dependent allergic reactions have been published because of the illegal status of cannabis. However, it is becoming more prevalent as a potential allergen. For example, in Nebraska, C.sativa pollen accounts for 36% of the total pollen count.

People with IgE-mediated cannabis allergy can have a sensitization to the nonspecific lipid transfer protein of C.sativa, Cans3, which might explain the secondary plant-derived food allergies seen in European patients with a cannabis allergy, according to the review. Cans3 cross-reacts with various plant homologues.

"This is the sort of information that allergists need to have," Silvers said.

The fact that federal law prohibits cannabis use in the United States has made research difficult.

A strain distributed by the University of Mississippi can be used for research, "but it's potency is very low, at 5% or 7%," Silvers explained. At medical marijuana dispensaries, the potency of the flower can be as high as 25%, and in other forms, the THC content can be above 80%.

The legal status makes cannabis allergy difficult to diagnose and impossible to treat. Immunotherapy is out of the question. "With federal illegality, we need to stay out of trouble in that regard," said Silvers, adding that, currently, avoidance is advised.

But research is emerging from Canada, where medicinal and recreational marijuana use is legal. Results from a survey showing the prevalence of response in marijuana-exposed allergic patients will be reported at the meeting by Ryan Lo, MD, from the University of Toronto.

The impact of cannabis exposure on human respiratory health will be addressed by several speakers, including Angela Lemons, from the National Institute for Occupational Safety and Health in the United States.

Stigma around cannabis is still high. "Nobody wants to be seen as a 'pot doctor'," said Silvers. But after it became legal in Colorado in 2015, he was asked to give a talk and decided to speak up.

"I have never written a medical prescription for marijuana," he said, explaining that he is involved with the Center for Bioethics and Humanities at the University of Colorado. "I try to take a societal as well as a medical perspective, looking at the value and concerns for abuse and misuse."

"As it becomes more available, more legalized, patients are having more reactions," he said. "Allergists need to get in the game."

Attitudes need to change. Physicians and allergists need to understand what's happening in the population "and be open-minded about it so they know what to do," he added.

Users of medical marijuana can become dependent, said Ellen Burnham, MD, also from the University of Colorado.

"Patients want a blessing from care providers that it's okay to use," she told Medscape Medical News. "We're in a state where people are really interested in holistic approaches to health, and cannabis is a natural product, but it may exacerbate allergies."

Some components of cannabis might have bronchodilator properties but there are so many unknowns at this time. "I don't think allergists should be recommending or condoning cannabis as part of a patient's therapy," she said. "It's not okay for everybody."

As business flourishes for operators in the cannabis industry and for the legal profession, Burnham said she worries that there isn't enough protection for workers. "Do workers exposed to plant material on a daily basis have adequate workplace protection," such as masks and gowns? "There's a downstream effect that impacts people that nobody has really thought about," she pointed out.

If the cannabis industry becomes driven by money, with a lobby like the tobacco industry, there will be no way to keep people who are vulnerable from using cannabis.

Is an occasional joint, much like an occasional glass of wine, okay? "We don't know," said Burnham. "We just don't have enough information about it."

Research is needed to develop medicinal strains of cannabidiol, cannabigerol, and cannabinol, which offer "medicinal and anti-inflammatory relief without the psychologic affects," Silvers added.

American Academy of Allergy, Asthma and Immunology (AAAAI) 2020 Meeting.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the article here:
Marijuana Allergies on the Rise - Medscape

School of Medicine physicians, researchers tackle coronavirus Washington University School of Medicine in St. Louis – Washington University School of…

Visit the News Hub

Clinical teams ready; research for vaccines, drugs underway

Postdoctoral researchers Brett Case, PhD, (left) and Adam Bailey, MD, PhD, wear full personal protective equipment to study the COVID-19 virus. Washington University School of Medicine in St. Louis physicians and researchers are preparing for COVID-19 cases and working on drugs and vaccines to fight the disease.

Soon after a novel coronavirus first appeared in China in late 2019, researchers, doctors and staff at Washington University School of Medicine in St. Louis began preparing for the possibility of an outbreak. Infectious disease physicians started planning how to respond if a person with suspected exposure to the virus arrived on campus, and researchers set to work finding drugs or vaccines to treat or prevent COVID-19, the name given to the illness caused by the virus.

New infectious diseases emerge every so often, and we have to be vigilant, said Steven J. Lawrence, MD, an associate professor of medicine. Over the last few decades weve had HIV, Ebola, SARS, Zika and now COVID-19. Such diseases usually arise when an animal virus manages to jump into people because of close contact between people and animals. The chance of preventing that happening anywhere in the world is probably zero. What we can do is be prepared to respond as rapidly as possible when it happens.

In December, China reported the first cases of a mysterious illness characterized by fever, a dry cough and difficulty breathing. Within weeks, Chinese scientists had identified the cause as a never-before-seen member of the coronavirus family. Coronaviruses typically cause mild infections such as the common cold. But in 2002, a newly emerged strain of coronavirus caused an outbreak of severe acute respiratory syndrome (SARS) that killed nearly 1,000 people before it was contained.

It quickly became evident that the 2019 coronavirus strain, named SARS-CoV-2, was more like SARS than the common cold. By late January, tens of thousands of people in China were infected. At the time, the only cases in the U.S. were believed to be in people who had been infected while traveling in China.

In January and February, we had a brief moment of opportunity to contain this outbreak in the U.S. by knowing where people had traveled, Lawrence said. Thats why the efforts to identify and isolate people with the virus were so robust, even though we had such few cases. Once the virus started spreading from person to person in the U.S., it became much, much more complicated.

Washington University infectious disease physicians (from left) Stephen Y. Liang, MD, Steven J. Lawrence, MD, Hilary M. Babcock, MD, and David K. Warren, MD, are preparing for the possibility of COVID-19 cases in St. Louis. Pictured is the team, in 2014, discussing emerging infectious diseases.

Hilary M. Babcock, MD, a professor of medicine and medical director of the Infection Prevention and Epidemiology Consortium for BJC HealthCare, and David K. Warren, MD, a professor of medicine and the medical director for infection prevention at Barnes-Jewish Hospital, did not wait for the virus to start spreading in the U.S. In January, they established a virtual incident command center at BJCHealthCare and called twice-weekly meetings to develop a coronavirus outbreak response plan for all BJC hospitals, including hospitals and clinics staffed by Washington University physicians. The team started by dusting off a plan developed in 2002 for SARS and adapting it to COVID-19 as more information emerged.

The data on mortality for COVID-19 remains a moving target and continues to be assessed. So far, people who are older and those with underlying health conditions, such as heart disease, lung disease or with compromised immune systems, have a higher risk of death. Early data suggests that the illness is more deadly than seasonal flu. Like SARS and the flu, COVID-19 spreads easily through droplets released when infected people cough or sneeze. The viruss contagiousness means that proper use of personal protective equipment is crucial to protect health professionals caring for coronavirus patients.

Communication is one of the most important tools at a time like this, Babcock said. We needed to make sure that our front-line clinicians can very quickly recognize that someone might be infected, and that they know what to do if a potentially infected person presents at their clinic. We also developed guidance regarding which personal protective equipment to wear when working with a patient suspected of having COVID-19 mask, gloves, eye shield, respiratory equipment, and gown how to put it on so it is most effective, and, most importantly, how to take it off without contaminating yourself.

Babcock and Warren also are keeping a close watch on outbreaks in other countries and implemented new travel screening recommendations across the university as the virus has spread to other countries, notably South Korea, Italy and Iran.

We are ready, Babcock said. Weve been ready for weeks. Its only a matter of time before we get our first case.

Building the toolkit to fight COVID-19

Across campus, a team led by Sean Whelan, PhD, the Marvin A. Brennecke Distinguished Professor and head of the Department of Molecular Microbiology, and Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, is looking for ways to treat COVID-19 or reduce its spread.

We had a discussion in early January and decided then to work on advancing therapeutics and vaccines for coronavirus, because it had the potential to be a significant problem, said Whelan, who took over as head of the molecular microbiology department on Jan. 1. It is our responsibility as part of the biomedical research community to do this. The consequences of this virus in places where there isnt a good health-care system could be dire.

Whelan called weekly meetings to coordinate the School of Medicine coronavirus research effort. He and Diamond have special expertise in emerging viral infections. Diamond led the School of Medicine response to Zika virus, during which he and others developed a mouse model of Zika infection and identified an antibody that is now used as part of a diagnostic test. While on the faculty at Harvard, Whelan studied Ebola and identified a critical protein that the virus exploits to cause deadly infections.

Whelan and Diamond built a research team including influenza experts Jacco Boon, PhD, an associate professor of medicine, and Ali Ellebedy, PhD, an assistant professor of pathology and immunology, who provided advice and scientific tools for studying respiratory viruses; structural immunologist Daved Fremont, PhD, a professor of pathology and immunology, who has begun studying the interactions of coronavirus proteins with antibodies and other human proteins to facilitate vaccine design and improved diagnostics; David T. Curiel, MD, PhD, the Distinguished Professor of Radiation Oncology,who began designing a potential vaccine; and Siyuan Ding, PhD, an assistant professor of molecular microbiology, who is investigating whether the virus also can be transmitted through the fecal-oral route.

The team is analyzing the structure of the viruss proteins to find possible targets for drugs or vaccines, looking for antibodies that might protect against disease, creating potential vaccines using multiple strategies, and developing a mouse model that can be used to test potential drugs and vaccines.

In addition, geneticist Ting Wang, PhD, the Sanford and Karen Loewentheil Distinguished Professor of Medicine, and members of his lab built a genome browser to help researchers study the genetics of the COVID-19 virus and compare different strains. Greg Bowman, PhD, an associate professor of biochemistry and molecular biophysics whose work focuses on how proteins take their shape, has mobilized his crowdsourced Folding@home Consortium to find the shape of coronavirus proteins to inform drug and vaccine development.

The speed of research on coronavirus has been extraordinary, Diamond said. Chinese scientists identified the virus, sequenced its genome, identified the probable animal source, and released the genomic sequence to the public in a matter of weeks. Groups around the world have been creating and sharing the tools we need to interrogate this virus. But even so, these things take time. Every day, the U.S. is seeing new cases. We are racing against the clock.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

More here:
School of Medicine physicians, researchers tackle coronavirus Washington University School of Medicine in St. Louis - Washington University School of...